Endoxifen Usage in Bipolar Disorders Patients: My Experiential Journey

Abstract

Bipolar affective disorder is a severe mental illness that affects 0.3% of the Indian population, as estimated in the National Mental Health Survey 2016.1 Antipsychotic drugs and mood stabilizers have both been used as first-line agents in the treatment of the manic phase of bipolar I disorder, either singly or in combination. Tamoxifen, a protein kinase C (PKC) inhibitor, has shown efficacy in the treatment of the manic phase of bipolar I disorder. Tamoxifen is recommended as a third-line agent in the treatment of bipolar mania, as per CANMAT and ISBD 2019 treatment guidelines on bipolar disorder.2